JP2018524393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524393A5 JP2018524393A5 JP2018503747A JP2018503747A JP2018524393A5 JP 2018524393 A5 JP2018524393 A5 JP 2018524393A5 JP 2018503747 A JP2018503747 A JP 2018503747A JP 2018503747 A JP2018503747 A JP 2018503747A JP 2018524393 A5 JP2018524393 A5 JP 2018524393A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- adenovirus
- antigen
- seq
- related antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091007433 antigens Proteins 0.000 claims description 188
- 102000036639 antigens Human genes 0.000 claims description 188
- 239000000427 antigen Substances 0.000 claims description 187
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 150
- 229920001184 polypeptide Polymers 0.000 claims description 148
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 148
- 241000701161 unidentified adenovirus Species 0.000 claims description 99
- 241000990167 unclassified Simian adenoviruses Species 0.000 claims description 96
- 230000028993 immune response Effects 0.000 claims description 19
- 230000001939 inductive effect Effects 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims description 8
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 108700019146 Transgenes Proteins 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 241001217856 Chimpanzee adenovirus Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 60
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 3
- 101150029662 E1 gene Proteins 0.000 description 2
- 101150005585 E3 gene Proteins 0.000 description 2
- 101150066038 E4 gene Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1513176.6 | 2015-07-27 | ||
| GBGB1513176.6A GB201513176D0 (en) | 2015-07-27 | 2015-07-27 | Novel methods for inducing an immune response |
| PCT/EP2016/067622 WO2017017050A1 (en) | 2015-07-27 | 2016-07-25 | Novel methods for inducing an immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018524393A JP2018524393A (ja) | 2018-08-30 |
| JP2018524393A5 true JP2018524393A5 (https=) | 2019-09-05 |
Family
ID=54106649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503747A Pending JP2018524393A (ja) | 2015-07-27 | 2016-07-25 | 免疫応答を誘導するための新規方法 |
| JP2018504131A Pending JP2018521666A (ja) | 2015-07-27 | 2016-07-25 | 新規アデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504131A Pending JP2018521666A (ja) | 2015-07-27 | 2016-07-25 | 新規アデノウイルス |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20180216081A1 (https=) |
| EP (2) | EP3328420A1 (https=) |
| JP (2) | JP2018524393A (https=) |
| KR (1) | KR20180034589A (https=) |
| CN (2) | CN108367061A (https=) |
| AR (1) | AR105470A1 (https=) |
| AU (1) | AU2016301029B2 (https=) |
| BE (2) | BE1023915B1 (https=) |
| BR (2) | BR112018001683A2 (https=) |
| CA (2) | CA2993277A1 (https=) |
| EA (1) | EA201890355A1 (https=) |
| GB (1) | GB201513176D0 (https=) |
| IL (1) | IL257071A (https=) |
| MX (2) | MX2018001213A (https=) |
| WO (2) | WO2017017050A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| KR20250081944A (ko) | 2014-09-24 | 2025-06-05 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP4155411A1 (en) | 2016-02-23 | 2023-03-29 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| EP3436591B1 (en) * | 2016-03-31 | 2023-01-04 | The European Molecular Biology Laboratory | Adenoviral coat protein derived delivery vehicles |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| CN111527213A (zh) | 2017-10-16 | 2020-08-11 | 葛兰素史密丝克莱恩生物有限公司 | 具有两个编码rsv抗原蛋白或片段的表达盒的腺病毒载体 |
| CA3084358A1 (en) * | 2017-10-16 | 2019-04-25 | Glaxosmithkline Biologicals Sa | Enhanced promoter |
| US20200299651A1 (en) * | 2017-10-16 | 2020-09-24 | Glaxosmithkline Biologicals Sa | Simian adenoviral vectors with two expression cassettes |
| AU2018351308B2 (en) * | 2017-10-16 | 2021-12-02 | Glaxosmithkline Biologicals Sa | Replication competent adenoviral vectors |
| GB201721069D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| MX2020010499A (es) | 2018-04-09 | 2020-10-28 | Salk Inst For Biological Studi | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. |
| JP2021526831A (ja) * | 2018-06-12 | 2021-10-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アデノウイルスポリヌクレオチド及びポリペプチド |
| WO2020033876A1 (en) * | 2018-08-10 | 2020-02-13 | Nantbio, Inc. | Cellular adjuvants for viral infection |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN110283766B (zh) * | 2019-05-13 | 2020-12-18 | 华中科技大学 | 一种重组卡介苗及其构建与应用 |
| CN110606875A (zh) * | 2019-09-20 | 2019-12-24 | 中国农业科学院兰州兽医研究所 | 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗 |
| CA3153133A1 (en) * | 2019-09-30 | 2021-04-08 | Chris Bartolome | Adeno-associated virus (aav) systems for treatment of genetic hearing loss |
| CN113088538A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法 |
| CN113088530A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法 |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN114438128A (zh) * | 2020-10-30 | 2022-05-06 | 上海市公共卫生临床中心 | 一种增强型溶瘤腺病毒及其应用 |
| US20240033334A1 (en) * | 2020-12-04 | 2024-02-01 | Gritstone Bio, Inc. | Compositions and methods of use thereof |
| WO2023034783A1 (en) * | 2021-08-31 | 2023-03-09 | Vir Biotechnology, Inc. | Tuberculosis vaccines |
| CN118662620A (zh) * | 2023-03-15 | 2024-09-20 | 康希诺生物股份公司 | 一种肺结核疫苗及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200901109T1 (tr) | 1995-09-01 | 2012-02-21 | Corixa Corporation | Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler |
| US6350456B1 (en) * | 1997-03-13 | 2002-02-26 | Corixa Corporation | Compositions and methods for the prevention and treatment of M. tuberculosis infection |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US7083796B2 (en) * | 2000-06-20 | 2006-08-01 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US7026465B2 (en) | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| US9592284B2 (en) | 2004-04-28 | 2017-03-14 | The Trustees Of The University Of Pennsylvania | Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost |
| EP2426141B1 (en) * | 2005-04-29 | 2014-10-01 | GlaxoSmithKline Biologicals S.A. | Method for preventing or treating M tuberculosis infection |
| WO2006133911A2 (en) * | 2005-06-17 | 2006-12-21 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hepatitis c virus nucleic acid vaccine |
| HRP20161606T1 (hr) | 2007-03-02 | 2017-01-13 | Glaxosmithkline Biologicals Sa | Novi postupak i pripravci |
| EP2463362B1 (en) * | 2007-11-28 | 2017-11-08 | The Trustees Of The University Of Pennsylvania | Simian subfamily c adenovirus SAdv-31 and uses thereof |
| GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
| EP2391638B1 (en) * | 2009-02-02 | 2018-06-27 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| GB0918154D0 (en) | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
| SI2528621T1 (sl) * | 2010-01-27 | 2017-01-31 | Glaxosmithkline Biologicals S.A., | Modificirani tuberkolozni antigeni |
| EP2560680B1 (en) * | 2010-04-16 | 2018-11-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
| PL2651436T3 (pl) * | 2010-12-14 | 2016-10-31 | Kompozycja antygenów mykobakteryjnych | |
| WO2013123579A1 (en) * | 2012-02-24 | 2013-08-29 | Mcmaster University | Adenovirus-based tuberculosis vaccine and its use |
| CN107921118B (zh) | 2015-06-12 | 2022-11-08 | 葛兰素史密丝克莱恩生物有限公司 | 腺病毒多核苷酸和多肽 |
-
2015
- 2015-07-27 GB GBGB1513176.6A patent/GB201513176D0/en not_active Ceased
-
2016
- 2016-07-25 MX MX2018001213A patent/MX2018001213A/es unknown
- 2016-07-25 US US15/747,545 patent/US20180216081A1/en not_active Abandoned
- 2016-07-25 CN CN201680043249.8A patent/CN108367061A/zh active Pending
- 2016-07-25 CA CA2993277A patent/CA2993277A1/en not_active Abandoned
- 2016-07-25 EP EP16741946.4A patent/EP3328420A1/en not_active Withdrawn
- 2016-07-25 JP JP2018503747A patent/JP2018524393A/ja active Pending
- 2016-07-25 WO PCT/EP2016/067622 patent/WO2017017050A1/en not_active Ceased
- 2016-07-25 AU AU2016301029A patent/AU2016301029B2/en not_active Ceased
- 2016-07-25 JP JP2018504131A patent/JP2018521666A/ja active Pending
- 2016-07-25 CA CA2993371A patent/CA2993371A1/en not_active Abandoned
- 2016-07-25 CN CN201680056024.6A patent/CN108135991A/zh active Pending
- 2016-07-25 WO PCT/EP2016/067621 patent/WO2017017049A1/en not_active Ceased
- 2016-07-25 BR BR112018001683A patent/BR112018001683A2/pt not_active Application Discontinuation
- 2016-07-25 AR ARP160102263A patent/AR105470A1/es unknown
- 2016-07-25 MX MX2018001215A patent/MX2018001215A/es unknown
- 2016-07-25 EA EA201890355A patent/EA201890355A1/ru unknown
- 2016-07-25 BE BE20165611A patent/BE1023915B1/fr not_active IP Right Cessation
- 2016-07-25 BE BE20165610A patent/BE1023916A9/fr not_active IP Right Cessation
- 2016-07-25 EP EP16745090.7A patent/EP3328421A1/en not_active Withdrawn
- 2016-07-25 KR KR1020187005661A patent/KR20180034589A/ko not_active Withdrawn
- 2016-07-25 BR BR112018001572A patent/BR112018001572A2/pt not_active Application Discontinuation
- 2016-07-25 US US15/747,671 patent/US11110159B2/en not_active Expired - Fee Related
-
2018
- 2018-01-22 IL IL257071A patent/IL257071A/en unknown
-
2020
- 2020-08-06 US US16/986,413 patent/US20210060150A1/en not_active Abandoned
-
2021
- 2021-08-09 US US17/397,379 patent/US20210386846A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524393A5 (https=) | ||
| CN102666575B (zh) | 分枝杆菌疫苗 | |
| JP5555431B2 (ja) | 自己免疫疾患を予防し治療するための物質 | |
| JP2008530245A5 (https=) | ||
| JP2014527404A5 (https=) | ||
| JP2018513678A5 (https=) | ||
| JP2020528911A5 (https=) | ||
| WO2003075952A1 (en) | Methods of enhancing immune induction involving mda-7 | |
| JP2024043538A (ja) | B型肝炎ワクチンおよびその使用 | |
| CN111741766A (zh) | 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 | |
| HK1259146A1 (zh) | 用於流感疫苗接种的方法和组合物 | |
| KR20230113331A (ko) | 인간 파필로마 바이러스 백신 및 hpv 연관된 질환에 대한 이의 용도 | |
| US20220226459A1 (en) | Dosage regimens for vaccines | |
| US9676825B2 (en) | Chimeric vaccine antigens against hepatitis C virus | |
| Basirnejad et al. | Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant | |
| JP2025504364A (ja) | 慢性b型肝炎感染症を処置または防止するための複数抗原治療ワクチン | |
| JPWO2022187424A5 (https=) | ||
| US11097001B1 (en) | Composition and method against tuberculosis | |
| US20190276502A1 (en) | Fusion polypeptides derived from staphylococcus aureus antigens | |
| RU2024104848A (ru) | Рекомбинантный антиген для индукции иммунного ответа против вируса зика | |
| RU2023124900A (ru) | Композиции, содержащие адъюванты sbi, и способы их применения | |
| KR20220145736A (ko) | 코로나바이러스감염증 예방용 백신의 투여 및 용량 | |
| JP2014505700A (ja) | 抗原性gly1ポリペプチド |